Opening book details…
Can I read Angiotensin–neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure on EtoBox?
Angiotensin–neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure by Finnian R. Mc Causland; Martin P. Lefkowitz; Brian Claggett; Milton Packer; Michele Senni; Mauro Gori; Pardeep S. Jhund; Martina M. McGrath; Jean L. Rouleau; Victor Shi; Karl Swedberg; Muthiah Vaduganathan; Faiez Zannad; Marc A. Pfeffer; Michael Zile; John J.V. McMurray; Scott D. Solomon is a Medicine article available to read on EtoBox.
What is Angiotensin–neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure about?
## Abstract ## Aims Patients with heart failure are at higher risk of progression to end‐stage renal disease (ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin–neprilysin inhibition in a pooled analysis of 13 195 patients with heart failure with reduced and preserved EF. ## Methods and results We combined data from PARADIGM‐HF (EF ≤40%; n = 8399) and PARAGON‐HF (EF ≥45%; n = 4796) in a pre‐specified pooled analysis. We assessed the effect of treatment (sacubitril/valsartan vs. enalapril or valsartan) on a composite of either ≥50% reduction in estimated glomerular filtration rate (eGFR), ESRD, or death from renal causes, in addition to changes in eGFR slope. We assessed whether baseline renal function or EF modified the effect of therapy on renal outcomes. At randomization, eGFR was 68 ± 20 ml/min/1.73 m^2^ in PARADIGM‐HF and 63 ± 19 ml/min/1.73 m^2^ in PARAGON‐HF. The composite renal outcome occurred in 70 of 6594 patients (1.1%) in the sacubitril/valsartan group and in 123 of 6601 patients (1.9%) in the valsartan or enalapril group (hazard ratio 0.56, 95% confidence interval [CI] 0.42–0.75; p < 0.001). The mean eGFR change was −1.8 (95% CI −
Who reads Angiotensin–neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Finnian R. Mc Causland; Martin P. Lefkowitz; Brian Claggett; Milton Packer; Michele Senni; Mauro Gori; Pardeep S. Jhund; Martina M. McGrath; Jean L. Rouleau; Victor Shi; Karl Swedberg; Muthiah Vaduganathan; Faiez Zannad; Marc A. Pfeffer; Michael Zile; John J.V. McMurray; Scott D. Solomon
- Publisher
- Wiley
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)